Skip to main content
MNKDMannKind CorporationSell6.4·$3.90

MannKind (MNKD) Q3 2026 earnings — TrendMatrix coverage

IN LINE-33.3% vs estimateEPS -$0.01 vs -$0.01 estVerdict Hold → Sell

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy

Event detail · Q3 2026

Key numbers

Adjusted EPS
-$0.01
Estimate
-$0.01
Surprise
-33.3%
Revenue (period 2026-09-30)
$101.9M
Score at report (before → after)
6.5 → 6.5/10

Revenue source: xbrl.

Report record · Q3 2026

How the report landed

MannKind (MNKD) reported adjusted EPS of -$0.01, in line with the -$0.01 estimate. TrendMatrix's engine moved from Hold (6.5/10) to Sell at 6.5/10 after the report.

Around the report

Coverage in the report window

  • Cantor Fitzgerald Maintains Overweight on MannKind, Raises Price Target to $10 — benzinga, 2026-11-06
  • MannKind Corporation Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-05
  • MannKind Q3 Adj. EPS $(0.01) Beats $(0.06) Estimate, Sales $101.870M Miss $107.750M Estimate — benzinga, 2026-11-05
Current read · as of 2026-11-06

Where TrendMatrix's rating stands now

TrendMatrix currently rates MNKD Sell at 6.4/10.

0 of the last 4 quarters beat the estimate; this quarter's -33.3% surprise compares with a -264.2% four-quarter average.

What supports the rating

  • Sector modifier (Healthcare): +0.5
  • Attractive valuation

What argues against it

  • Concentration risk — Supplier: Amphastar (sole insulin supplier for Afrezza)
  • V7 low-quality RISK_OFF penalty: -0.5 (Q=5.2)
  • Consecutive earnings misses (3)

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$3.90
Price target
$7.03
Stop
$3.63
Upside to target
+80.3%
Reward-to-risk
5.3:1

Risk check: RSI 82 — a level conventionally read as overbought; gains at these levels often lean on momentum.

Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.

Healthcare context

MNKD at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Biotechnology
Market cap
$1.21B
P/E (fwd)
27.9
52-week range
$2.23–$6.51
Off 52-week high
40.1%
RSI (14)
82
Volume vs avg
0.45×
Score today
6.4/10

EPS and the estimate come from Yahoo Finance’s earnings calendar, captured around the report date. That EPS is the adjusted figure analysts forecast, so it can differ from the GAAP diluted EPS in the company’s filing, and consensus estimates vary between data providers. Revenue comes from SEC XBRL company facts where available, yfinance-provisional otherwise. Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home › Stocks › MNKD › Earnings › Q3 2026 earnings